Eris (EG.5), a new COVID-19 strain, gains WHO’s variant of interest status. Global prevalence increases, yet it’s assessed as a low global risk. While more transmissible, it shows no heightened disease severity. Eris is related to Omicron’s XBB.1.9.2 subvariant, with some immune evasion tendencies. Common symptoms include mild cough, headaches, and runny nose.WHO declares Eris a COVID variant of interest
Eris (EG.5), a new COVID-19 strain, gains WHO’s variant of interest status. Global prevalence increases, yet it’s assessed as a low global risk. While more transmissible, it shows no heightened disease severity. Eris is related to Omicron’s XBB.1.9.2 subvariant, with some immune evasion tendencies. Common symptoms include mild cough, headaches, and runny nose.
